文献速递乳腺癌

激素受体阳性/HER2阴性转移性乳腺癌的个体化治疗

Personalizing therapies over the course of hormone receptor-positive/HER2-negative metastatic breast cancer.
PubMed 文献 · CA Cancer J Clin · 2026-01-01

本综述总结激素受体阳性/HER2阴性转移性乳腺癌的生物学特征,重点阐述内在和获得性耐药机制,包括驱动基因组变异如何结合临床因素指导治疗选择和排序。文中讨论基因组和转录组分析如何辅助治疗决策,并综述CDK4/6、PI3K和AKT抑制剂及新一代雌激素受体降解剂等靶向治疗进展,以及抗体药物偶联物和生物标志物引导的肿瘤不可知生物疗法的扩展作用。

要点

  • 内分泌治疗仍是基石,但几乎所有患者最终出现耐药。
  • 基因组和转录组分析可指导治疗选择与序贯策略。
  • CDK4/6、PI3K、AKT抑制剂和新型ER降解剂等靶向药物进展丰富治疗选择。

核心结论

  • 现代治疗格局强调整合临床特征、生物标志物和患者偏好的个体化方法,贯穿疾病全程。

研究设计与样本

  • 本综述总结激素受体阳性/HER2阴性转移性乳腺癌的生物学、耐药机制及治疗进展。

主要发现

  • 激素受体阳性/HER2阴性转移性乳腺癌病程相对较长但存在异质性,内分泌治疗为基础但最终耐药。
  • 驱动基因组变异结合临床因素有助于指导治疗选择和排序。
  • 靶向治疗如CDK4/6、PI3K、AKT抑制剂和下一代雌激素受体降解剂、抗体药物偶联物及生物标志物引导的肿瘤不可知生物疗法作用扩展。
  • 肿瘤微环境对耐药和疾病进展的影响及浸润性小叶癌的独特临床行为受到关注。

关键数值与推荐

  • 基因组和转录组分析用于指导治疗选择,副作用和患者整体体验纳入决策。

临床怎么用

  • 临床实践中应整合临床特征、生物标志物和患者偏好制定个体化治疗计划。
  • 患者报告结局、共享决策和真实世界证据有助于制定综合护理计划、指南和政策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer subtype accounts for most early and metastatic breast cancer (MBC) cases. HR-positive/HER2-negative MBC is characterized by a relatively prolonged, although variable, disease course and substantial intertumoral and intratumoral heterogeneity. Although endocrine-based therapies remain the cornerstone of treatment, nearly all patients eventually develop resistance, which is increasingly addressed with biologically targeted agents and newer-generation cytotoxic drugs. This review summarizes the current understanding of HR-positive/HER2-negative MBC biology, highlighting mechanisms of intrinsic and acquired resistance, including driver genomic alterations that, along with clinical factors, help guide therapeutic choices and sequencing. The authors specify and discuss how genomic and transcriptomic profiling inform treatment selection and how side effects and overall patient experience are considered in decision making. Advances in targeted therapies, such as CDK4/6 (cyclin-dependent kinase 4/6), PI3K (phosphatidylinositol 3-kinase), and AKT (protein kinase B) inhibitors, and next-generation estrogen receptor degraders are reviewed along with the expanding role of antibody-drug conjugates and biomarker-guided tumor-agnostic biologic therapies. The authors also explore evolving biologic concepts, including the impact of the tumor microenvironment on resistance and disease progression, and consider the distinct clinical behavior of invasive lobular carcinoma and current approaches. Emerging data from contemporary clinical trials promise to refine clinical and biomarker-driven algorithms and improve outcomes for patients with HR-positive/HER2-negative MBC. Ongoing multi-omic research and adaptive clinical strategies will be essential to further the application of precision oncology in this most common subtype of MBC. Importantly, patient-reported outcomes, shared decision making, and real-world evidence are increasingly useful in formulating comprehensive care plans, guidelines, and policy. The modern treatment landscape features a personalized approach that integrates clinical features, biomarkers, and patient preferences across the disease continuum.

来源:CA Cancer J Clin,查看原文。版权归原作者所有。

引用

  1. Singareeka Raghavendra A, Damodaran S, Barcenas CH, et al. Personalizing therapies over the course of hormone receptor-positive/HER2-negative metastatic breast cancer. CA Cancer J Clin. 2026. PMID: 41524544. doi:10.3322/caac.70055

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。